Τίτλος:
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background Fibroblast growth factor (FGF) 23 is a hormone that increases urinary phosphate excretion and regulates renal sodium reabsorption and plasma volume. We studied the role of plasma FGF23 in therapy optimization and outcomes in patients with new-onset and worsening heart failure (HF). Methods We measured plasma C-terminal FGF23 levels at baseline in 2399 of the 2516 patients included in the BIOlogy Study to Tailored Treatment in Chronic HF (BIOSTAT-CHF) trial. The association between FGF23 and outcome was evaluated by Cox regression analysis adjusted for potential confounders. Results Median FGF23 was 218.0 [IQR: 117.1–579.3] RU/ml; patients with higher FGF23 levels had a worse NYHA class, more signs of congestion, and were less likely to use an ACE-inhibitor (ACEi) or angiotensin receptor blocker (ARBs) at baseline (all P < 0.01). Higher FGF23 levels were independently associated with higher BNP, lower eGFR, the presence of oedema and atrial fibrillation (all P < 0.001). In addition, higher FGF23 was independently associated with impaired uptitration of ACEi/ARBs after 3 months, but not of beta-blockers. In multivariable Cox regression analysis, FGF23 was independently associated with all-cause mortality (hazard ratio: 1.17 (1.09–1.26) per log increase, P < 0.001), and the combined endpoint of all-cause mortality and HF hospitalization (1.15 (1.08–1.22) per log increase, P < 0.001). Conclusions In patients with new-onset and worsening HF, higher plasma FGF23 levels were independently associated with volume overload, less successful uptitration of ACEi/ARBs and an increased risk of all-cause mortality and HF hospitalization. © 2017 Elsevier B.V.
Συγγραφείς:
ter Maaten, J.M.
Voors, A.A.
Damman, K.
van der Meer, P.
Anker, S.D.
Cleland, J.G.
Dickstein, K.
Filippatos, G.
van der Harst, P.
Hillege, H.L.
Lang, C.C.
Metra, M.
Navis, G.
Ng, L.
Ouwerkerk, W.
Ponikowski, P.
Samani, N.J.
van Veldhuisen, D.J.
Zannad, F.
Zwinderman, A.H.
de Borst, M.H.
Περιοδικό:
International Journal of Cardiology
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
angiotensin receptor antagonist; beta adrenergic receptor blocking agent; brain natriuretic peptide; dipeptidyl carboxypeptidase inhibitor; fibroblast growth factor 23; furosemide; biological marker; fibroblast growth factor; fibroblast growth factor 23, aged; all cause mortality; Article; atrial fibrillation; cardiovascular mortality; confounding variable; controlled study; drug dose titration; edema; estimated glomerular filtration rate; female; general condition deterioration; heart failure; hospitalization; human; hypervolemia; independent variable; major clinical study; male; observational study; priority journal; prognosis; prospective study; protein blood level; treatment outcome; very elderly; blood; clinical trial; disease exacerbation; follow up; heart failure; heart stroke volume; international cooperation; middle aged; mortality; multicenter study; physiology; prognosis; treatment outcome; trends, Aged; Aged, 80 and over; Biomarkers; Disease Progression; Female; Fibroblast Growth Factors; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Internationality; Male; Middle Aged; Mortality; Prognosis; Prospective Studies; Stroke Volume; Treatment Outcome
DOI:
10.1016/j.ijcard.2017.10.010
